Literature DB >> 10022779

Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol.

C R Deible1, P Petrosko, P C Johnson, E J Beckman, A J Russell, W R Wagner.   

Abstract

For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. Polyethylene-glycol-diisocyanate(PEG-diisocyanate, 3400 MW) may potentially react with protein amines to form molecular barriers on adsorbed proteins on biomaterials, thereby masking adhesive ligands and preventing acute surface thrombosis. To test this notion, PE, PTFE, and glass microconduits were pre-adsorbed with fibrinogen and treated with PEG-diisocyanate, non-reactive PEG-dihydroxyl, or remained untreated. Following perfusion of 111In-labeled platelets in whole human blood for 1 min (wall shear rate = 312 s(-1)), PEG-diisocyanate treated surfaces experienced 96%(PE), 97%(PTFE) and 94% (glass) less platelet deposition than untreated surfaces. Similar reductions were seen for PEG-diisocyanate versus PEG-dihydroxyl treatment. Low shear perfusions of plasma for one hour prior to blood contact did not reduce the inhibitory effect of PEG-diisocyanate. Platelet adhesion onto collagen coated glass coverslips and platelet deposition onto preclotted Dacron was also reduced by treatment with PEG-diisocyanate (93 and 91%, respectively). Protein-reactive PEG may thus have utility in forming molecular barriers on surface associated proteins to inhibit acute thrombosis on cardiovascular biomaterials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022779     DOI: 10.1016/s0142-9612(98)00001-5

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

1.  Targeting microspheres and cells to polyethylene glycol-modified biological surfaces.

Authors:  Timothy E Deglau; Jermaine D Johnson; Flordeliza S Villanueva; William R Wagner
Journal:  J Biomed Mater Res A       Date:  2007-06-01       Impact factor: 4.396

2.  Real time visualization and characterization of platelet deposition under flow onto clinically relevant opaque surfaces.

Authors:  Megan A Jamiolkowski; Joshua R Woolley; Marina V Kameneva; James F Antaki; William R Wagner
Journal:  J Biomed Mater Res A       Date:  2014-05-06       Impact factor: 4.396

3.  Anti-platelet and tissue engineering approaches to biomaterial blood compatibilization: how well have these been translated into the clinic?

Authors:  Scott Alexander Irvine; Xia Yun; Subbu Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

Review 4.  In Vivo Chemical Sensors: Role of Biocompatibility on Performance and Utility.

Authors:  Robert J Soto; Jackson R Hall; Micah D Brown; James B Taylor; Mark H Schoenfisch
Journal:  Anal Chem       Date:  2016-11-21       Impact factor: 6.986

5.  Development of tannic acid-enriched materials modified by poly(ethylene glycol) for potential applications as wound dressing.

Authors:  Beata Kaczmarek; Olha Mazur; Oliwia Miłek; Marta Michalska-Sionkowska; Anna M Osyczka; Konrad Kleszczyński
Journal:  Prog Biomater       Date:  2020-09-20

6.  Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus.

Authors:  Bruce A Kerwin; Byeong S Chang; Colin V Gegg; Margherita Gonnelli; Tiansheng Li; Giovanni B Strambini
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

7.  Facile coupling of synthetic peptides and peptide-polymer conjugates to cartilage via transglutaminase enzyme.

Authors:  Marsha Elizabeth Ritter Jones; Phillip B Messersmith
Journal:  Biomaterials       Date:  2007-09-17       Impact factor: 12.479

8.  PDMS content affects in vitro hemocompatibility of synthetic vascular grafts.

Authors:  Dario Spiller; Paola Losi; Enrica Briganti; Silverio Sbrana; Silvia Kull; Ilaria Martinelli; Giorgio Soldani
Journal:  J Mater Sci Mater Med       Date:  2007-02-01       Impact factor: 4.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.